Javascript was detected to be disabled. Javascript is required for some functions on this website.

FROM KNOWLEDGE TO SOLUTIONS

Where scientific rigor meets real-world healthcare impact

InnoValHC is an independent, not-for-profit research organization dedicated to the advancement of applied health economics, combining scientific excellence, senior expertise from academia and industry, and a trusted international network of experts. The projects are supported by its management unit, InnoValHC Research Inc., to help stakeholders successfully navigate the most demanding challenges in health economics, HTA, value assessment, pricing and reimbursement, R&D management, and patient access.

Contact us to find out how we can best support you to convert complexity into evidence, value, and access.

Pixabay Grafik (#7562017)

Challenging the Logic of Cost Effectiveness

At ISPOR Europe 2026, Michael Schlander offered an overview of emerging findings from an ongoing project to critically assess the use and limitations of CETs to inform decisions on health care coverage.

Read more …

The Socioeconomic Impact of Cancer

At the European ISPOR 2026 Meeting, Michael Schlander outlined critical contents of a forthcoming White Paper on the Socioeconomic Impact of Cancer.

Read more …

New Publication in the Discussion Paper Series

Tangible interim results include a completed systematic literature search, the IV Working Paper No. 39/2026, summarizing key insights from the first phase of the ongoing cost effectiveness threshold (CET) project.

Read more …

Access to Rare and Complex Disease Therapies

Michael Schlander gave a presentation at the European Parliament in Brussels, Belgium, as part of the ´Health Leadership Mission for Rare Diseases´ (HLM4Rare) platform (July 01, 2026).

Read more …

Advancing Health Economics with Scientific Integrity

We believe that health economics should serve as a bridge between medical innovation and sustainable, value-based, patient-centered healthcare systems. As an independent, highly specialized advisory team, we maintain strict scientific credibility while delivering high-impact solutions. We reject the rigid, one-size-fits-all models of traditional value analyses and instead provide objective, evidence-based insights that serve both private life science companies, public research organizations, and healthcare policy makers.

Our research service offers are designed to support our partners at every stage of the research, regulatory, and patient access challenges. Whether we are building advanced economic models for commercial therapies, delivering executive education, or participating in large European research consortia as a trusted health economics partner, our work is always anchored in scientific rigor and transparent methodology. Explore our core pillars to see how rigorous science meets our commitment to improving patient lives and shaping a fairer healthcare system.

Webinars, Workshops & Executive Seminars

Webinars, in-house training sessions, tailored workshops, and executive seminars in applied health economics, HTA, and patient access, designed for experts and professionals shaping healthcare decisions:

Learn. Webinars and online programs with internal and external experts.
Apply. In-house training sessions and tailored workshops to your real business challenges.
Decide. Executive seminars for better-informed choices and decisions in healthcare.

Explore the InnoValHC Academy´s course portfolio …

Selected Projects

Cost Effectiveness Thresholds (CETs)

Michael Schlander, Ramon Schaefer, Maarten Postma, Søren Holm:

Cost Effectiveness Thresholds:
Ethical Considerations and Practical Reality

Initial Findings from an Integrative Review

IV Discussion Paper No. 39
© InnoValHC, Wiesbaden 2026
ISBN 978-3-941609-38-9

Working Paper

Initiated research project to understand the use of thresholds in the context of CEA, considering the relevant scientific literature, WHO statements, and policy recommendation, and to bring about a more balanced perspective on the roles and limitations of cost effectiveness thresholds (CETs), contributing to worldwide dialogues on their use in the context of HTA.

The Value of Laboratory Medicine

Michael Schlander, Ramon Schäfer, Lorenz Selberg:

Nutzen der Labormedizin
in der Schweiz

Berlin, Heidelberg: Springer 2023
ISBN 978-3-662-66824-5 (Softcover)
ISBN 978-3-662-66825-2 (eBook)
https://doi.org/10.1007/978-3-662-66825-2

Open Access Book

While experts believe that 70 % of all clinical decisions depend on laboratory test information, the cost effectiveness of many diagnostic procedures is subject to controversial debate.
With this publication, we provide insight into the value of laboratory medicine from the perspectives of patients, public health, and society at large, using the Swiss health care system as a case study.